Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $25.40.

KURA has been the topic of a number of recent research reports. Sanford C. Bernstein set a $24.00 price objective on Kura Oncology in a research note on Monday, June 15th. Oppenheimer set a $24.00 target price on Kura Oncology in a report on Thursday, May 28th. Wedbush increased their target price on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Raymond James Financial set a $24.00 price target on Kura Oncology in a research report on Monday, August 24th. Finally, Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, May 28th.

Insider Activity

In related news, insider Teresa Bair sold 31,487 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the sale, the insider owned 195,444 shares in the company, valued at approximately $2,468,457.72. This trade represents a 13.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian T. Powl sold 4,345 shares of Kura Oncology stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.89, for a total transaction of $51,662.05. Following the completion of the transaction, the insider directly owned 169,269 shares in the company, valued at $2,012,608.41. This trade represents a 2.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently modified their holdings of KURA. IFP Advisors Inc increased its stake in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares in the last quarter. Allworth Financial LP boosted its position in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Kura Oncology by 10.0% in the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock valued at $193,000 after buying an additional 1,692 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after buying an additional 1,888 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Kura Oncology by 11.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock valued at $194,000 after buying an additional 2,304 shares in the last quarter.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $11.73 on Wednesday. The company’s 50 day moving average price is $11.23 and its two-hundred day moving average price is $10.10. Kura Oncology has a 12-month low of $7.36 and a 12-month high of $13.90. The firm has a market cap of $1.04 billion, a PE ratio of -3.48 and a beta of 0.44. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. Equities research analysts predict that Kura Oncology will post -3.25 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.